{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:16:29Z","timestamp":1760148989827,"version":"build-2065373602"},"reference-count":82,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>(1) Background: Tuberous sclerosis complex (TSC) mutations directly affect mTORC activity and, as a result, protein synthesis. In several cancer types, TSC mutation is part of the driver mutation panel. TSC mutations have been associated with mitochondrial dysfunction, tolerance to reactive oxygen species due to increased thioredoxin reductase (TrxR) enzyme activity, tolerance to endoplasmic reticulum (ER) stress, and apoptosis. The FDA-approved drug rapamycin is frequently used in clinical applications to inhibit protein synthesis in cancers. Recently, TrxR inhibitor auranofin has also been involved in clinical trials to investigate the anticancer efficacy of the combination treatment with rapamycin. We aimed to investigate the molecular background of the efficacy of such drug combinations in treating neoplasia modulated by TSC mutations. (2) Methods: TSC2 mutant and TSC2 wild-type (WT) cell lines were exposed to rapamycin and auranofin in either mono- or combination treatment. Mitochondrial membrane potential, TrxR enzyme activity, stress protein array, mRNA and protein levels were investigated via cell proliferation assay, electron microscopy, etc. (3) Results: Auranofin and rapamycin normalized mitochondrial membrane potential and reduced proliferation capacity of TSC2 mutant cells. Database analysis identified peroxiredoxin 5 (Prdx5) as the joint target of auranofin and rapamycin. The auranofin and the combination of the two drugs reduced Prdx5 levels. The combination treatment increased the expression of heat shock protein 70, a cellular ER stress marker. (4) Conclusions: After extensive analyses, Prdx5 was identified as a shared target of the two drugs. The decreased Prdx5 protein level and the inhibition of both TrxR and mTOR by rapamycin and auranofin in the combination treatment made ER stress-induced cell death possible in TSC2 mutant cells.<\/jats:p>","DOI":"10.3390\/cells12131713","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T02:23:09Z","timestamp":1687746189000},"page":"1713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms"],"prefix":"10.3390","volume":"12","author":[{"given":"Judit","family":"Bovari-Biri","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pecs, 2. Rokus Str, H-7624 Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ElHusseiny Mohamed Mahmoud","family":"Abdelwahab","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pecs, 2. Rokus Str, H-7624 Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitti","family":"Garai","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pecs, 2. Rokus Str, H-7624 Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-5556","authenticated-orcid":false,"given":"Judit E.","family":"Pongracz","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pecs, 2. Rokus Str, H-7624 Pecs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3892\/etm.2021.9972","article-title":"PI3K\/AKT\/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review)","volume":"21","author":"Miricescu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.18632\/aging.100937","article-title":"Genetics of renal cancer: Focus on MTOR","volume":"8","author":"Ghosh","year":"2016","journal-title":"Aging"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The AACR Project GENIE Consortium (2017). AACR Project GENIEpowering precision medicine through an international consortium. Cancer Discov., 7, 818\u2013831.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/carcin\/bgq142","article-title":"Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1","volume":"31","author":"Slattery","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2005.03.023","article-title":"Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: The role of promoter methylation of TSC genes","volume":"41","author":"Jiang","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"eabi9533","DOI":"10.1126\/sciadv.abi9533","article-title":"Loss of TSC1\/TSC2 sensitizes immune checkpoint blockade in non\u2013small cell lung cancer","volume":"8","author":"Huang","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/1759-7714.12951","article-title":"TSC2 genetic variant and prognosis in non-small cell lung cancer after curative surgery","volume":"10","author":"Lee","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"665647","DOI":"10.3389\/fmed.2021.665647","article-title":"Recent Updates on the Involvement of PI3K\/AKT\/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders","volume":"8","author":"Mercurio","year":"2021","journal-title":"Front. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tan, F.H., Bai, Y., Saintigny, P., and Darido, C. (2019). mTOR Signalling in Head and Neck Cancer: Heads Up. Cells, 8.","DOI":"10.3390\/cells8040333"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/lrb.2009.0019","article-title":"mTOR signaling in lymphangioleiomyomatosis","volume":"8","author":"Kristof","year":"2010","journal-title":"Lymphat. Res. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.humpath.2007.01.028","article-title":"Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms","volume":"38","author":"Kenerson","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2011.04.008","article-title":"mTOR inhibitors in advanced renal cell carcinoma","volume":"25","author":"Voss","year":"2011","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Darici, S., Alkhaldi, H., Horne, G., J\u00f8rgensen, H.G., Marmiroli, S., and Huang, X. (2020). Targeting PI3K\/Akt\/mTOR in AML: Rationale and Clinical Evidence. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092934"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tian, T., Li, X., and Zhang, J. (2019). mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030755"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1158\/0008-5472.CAN-07-0325","article-title":"GRP78 induction in cancer: Therapeutic and prognostic implications","volume":"67","author":"Lee","year":"2007","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1089\/ars.2014.5851","article-title":"Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease","volume":"21","author":"Cao","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1007\/s00018-021-03756-3","article-title":"Crosstalk between endoplasmic reticulum stress and oxidative stress: A dynamic duo in multiple myeloma","volume":"78","author":"Xiong","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1038\/s41388-018-0625-1","article-title":"Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target","volume":"38","author":"Abdelwahab","year":"2019","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/cdd.2011.98","article-title":"mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway","volume":"19","author":"Kato","year":"2012","journal-title":"Cell. Death Differ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10495-021-01670-4","article-title":"Activated p53 in the anti-apoptotic milieu of tuberous sclerosis gene mutation induced diseases leads to cell death if thioredoxin reductase is inhibited","volume":"26","author":"Abdelwahab","year":"2021","journal-title":"Apoptosis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/thoraxjnl-2017-210872","article-title":"Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: A prospective national cohort study","volume":"73","author":"Bee","year":"2018","journal-title":"Thorax"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2014.10.508","article-title":"Mechanistic characterization of the thioredoxin system in the removal of hydrogen peroxide","volume":"78","author":"Pannala","year":"2015","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_24","first-page":"2788","article-title":"Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer","volume":"5","author":"Zhang","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11060-014-1661-5","article-title":"Tissue thioredoxin reductase-1 expression in astrocytomas of different grades","volume":"121","author":"Esen","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drup.2010.04.002","article-title":"Progress in the unraveling of the endoplasmic reticulum stress\/autophagy pathway and cancer: Implications for future therapeutic approaches","volume":"13","author":"Schleicher","year":"2010","journal-title":"Drug. Resist. Updat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41419-022-05081-4","article-title":"Beyond controlling cell size: Functional analyses of S6K in tumorigenesis","volume":"13","author":"Wu","year":"2022","journal-title":"Cell. Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/med.21872","article-title":"Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness","volume":"42","author":"Gamberi","year":"2022","journal-title":"Med. Res. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.7150\/thno.52077","article-title":"Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors","volume":"11","author":"Xia","year":"2021","journal-title":"Theranostics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"30787","DOI":"10.18632\/oncotarget.5021","article-title":"Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy","volume":"6","author":"Alves","year":"2015","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11971","DOI":"10.1038\/ncomms11971","article-title":"Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer","volume":"7","author":"Hao","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_32","unstructured":"Clinical Trial, I.N., and Mayo Clinic (2023, June 20). Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients with Recurrent Disease, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03456700."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e202100773","DOI":"10.1002\/cmdc.202100773","article-title":"Conception and Evaluation of Fluorescent Phosphine-Gold Complexes: From Synthesis to in\u2005vivo Investigations","volume":"17","author":"Rousselle","year":"2022","journal-title":"ChemMedChem"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0024-3205(95)02233-3","article-title":"Mechanism of action of the immunosuppressant rapamycin","volume":"58","author":"Dumont","year":"1996","journal-title":"Life Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ajpath.2016.03.009","article-title":"Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis","volume":"186","author":"Yue","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1073\/pnas.0712168105","article-title":"A chemical method for fast and sensitive detection of DNA synthesis in vivo","volume":"105","author":"Salic","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"pdb.prot087379","DOI":"10.1101\/pdb.prot087379","article-title":"Crystal Violet Assay for Determining Viability of Cultured Cells","volume":"2016","author":"Feoktistova","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Oka, M., Kobayashi, N., Matsumura, K., Nishio, M., and Saeki, K. (2019). Exogenous Cytokine-Free Differentiation of Human Pluripotent Stem Cells into Classical Brown Adipocytes. Cells, 8.","DOI":"10.3390\/cells8040373"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1089\/ars.2018.7697","article-title":"Which Antioxidant System Shapes Intracellular H","volume":"31","author":"Mishina","year":"2019","journal-title":"Antioxid. Redox Signal"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1029682","DOI":"10.3389\/fnmol.2022.1029682","article-title":"Ingenuity pathway analysis of","volume":"15","author":"Suthar","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"644592","DOI":"10.3389\/fonc.2021.644592","article-title":"Normalization of Enzyme Expression and Activity Regulating Vitamin A Metabolism Increases RAR-Beta Expression and Reduces Cellular Migration and Proliferation in Diseases Caused by Tuberous Sclerosis Gene Mutations","volume":"11","author":"Abdelwahab","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.peptides.2015.04.012","article-title":"A short history, principles, and types of ELISA, and our laboratory experience with peptide\/protein analyses using ELISA","volume":"72","author":"Aydin","year":"2015","journal-title":"Peptides"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12967-015-0403-6","article-title":"Profiling of cell stress protein expression in cardiac tissue of cardiosurgical patients undergoing remote ischemic preconditioning: Implications for thioredoxin in cardioprotection","volume":"13","author":"Zitta","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-022-02266-0","article-title":"Perfect match: mTOR inhibitors and tuberous sclerosis complex","volume":"17","author":"Luo","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biochi.2019.03.015","article-title":"Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug","volume":"162","author":"Zhang","year":"2019","journal-title":"Biochimie"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zeeshan, H.M., Lee, G.H., Kim, H.R., and Chae, H.J. (2016). Endoplasmic Reticulum Stress and Associated ROS. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030327"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3892\/mco.2017.1129","article-title":"The role of peroxiredoxins in cancer","volume":"6","author":"Nicolussi","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"20346","DOI":"10.1074\/jbc.M001943200","article-title":"Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate","volume":"275","author":"Seo","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_49","first-page":"3447","article-title":"Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity","volume":"40","author":"Lei","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2016.10.051","article-title":"Impaired Mitochondrial Dynamics and Mitophagy In Neuronal Models Of Tuberous Sclerosis Complex","volume":"17","author":"Saffari","year":"2016","journal-title":"Cell Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tcb.2010.03.004","article-title":"The regulation of energy metabolism and the IGF-1\/mTOR pathways by the p53 protein","volume":"20","author":"Feng","year":"2010","journal-title":"Trends Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"Yecies","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbamcr.2008.05.028","article-title":"Assembly of the oxidative phosphorylation system in humans: What we have learned by studying its defects","volume":"1793","author":"Tiranti","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3892\/ol.2012.928","article-title":"Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)","volume":"4","author":"Zheng","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","article-title":"AMPK: A nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"209845","DOI":"10.1155\/2014\/209845","article-title":"A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: A strange case of Dr. Jekyll and Mr. Hyde","volume":"2014","author":"Kwee","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/ars.2010.3584","article-title":"Peroxiredoxin 5: Structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin","volume":"15","author":"Knoops","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejca.2010.02.006","article-title":"Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis","volume":"46","author":"Puistola","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/his.12389","article-title":"Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas","volume":"65","author":"Bur","year":"2014","journal-title":"Histopathology"},{"key":"ref_61","first-page":"3418","article-title":"Peroxiredoxins in breast carcinoma","volume":"9","author":"Karihtala","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/thy.2005.15.205","article-title":"Peroxiredoxin 5 expression in the human thyroid gland","volume":"15","author":"Many","year":"2005","journal-title":"Thyroid."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00268-008-9521-0","article-title":"Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13","volume":"32","author":"Weng","year":"2008","journal-title":"World J. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2014.07.017","article-title":"Targeting antioxidants for cancer therapy","volume":"92","author":"Glasauer","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4197815","DOI":"10.1155\/2016\/4197815","article-title":"Reactive Oxygen Species in Cancer Biology and Anticancer Therapy","volume":"2016","author":"Bazhin","year":"2016","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_67","first-page":"73","article-title":"The role of peroxiredoxin II in chemoresistance of breast cancer cells","volume":"6","author":"Wang","year":"2014","journal-title":"Breast Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neulet.2007.12.068","article-title":"Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+","volume":"433","author":"Goemaere","year":"2008","journal-title":"Neurosci. Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"798483","DOI":"10.3389\/fonc.2022.798483","article-title":"Comprehensive Analysis of the PRDXs Family in Head and Neck Squamous Cell Carcinoma","volume":"12","author":"Cao","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.2147\/OTT.S181314","article-title":"Prognostic roles of mRNA expression of peroxiredoxins in lung cancer","volume":"11","author":"Chen","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3892\/ijmm.2020.4819","article-title":"ROS--mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC","volume":"47","author":"Cao","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"He, F., Ru, X., and Wen, T. (2020). NRF2, a Transcription Factor for Stress Response and Beyond. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134777"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jnc.12117","article-title":"Mitochondrial peroxiredoxin-5 as potential modulator of mitochondria-ER crosstalk in MPP+-induced cell death","volume":"125","author":"Linard","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.pathmechdis.3.121806.151434","article-title":"Endoplasmic reticulum stress in disease pathogenesis","volume":"3","author":"Lin","year":"2008","journal-title":"Annu. Rev. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0092-8674(00)80369-4","article-title":"The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response","volume":"90","author":"Sidrauski","year":"1997","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1101\/gad.992302","article-title":"ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats","volume":"16","author":"Nishitoh","year":"2002","journal-title":"Genes. Dev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1247\/csf.28.23","article-title":"Roles of MAPKKK ASK1 in stress-induced cell death","volume":"28","author":"Takeda","year":"2003","journal-title":"Cell Struct. Funct."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.01675-12","article-title":"A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia","volume":"57","author":"Miyamoto","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/ard.42.5.566","article-title":"Gold levels produced by treatment with auranofin and sodium aurothiomalate","volume":"42","author":"Lewis","year":"1983","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: Repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R&D"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2004.09.009","article-title":"Rapamycin: An anti-cancer immunosuppressant?","volume":"56","author":"Law","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_82","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2023, June 20). Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination, Available online: https:\/\/www.fda.gov\/files\/drugs\/published\/Codevelopment-of-Two-or-More-New-Investigational-Drugs-for-Use-in-Combination.pdf."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/13\/1713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:59:49Z","timestamp":1760126389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/13\/1713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":82,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cells12131713"],"URL":"https:\/\/doi.org\/10.3390\/cells12131713","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2023,6,24]]}}}